Stem cell transplantation for multiple myeloma: Current and future status Journal Article


Author: Giralt, S.
Article Title: Stem cell transplantation for multiple myeloma: Current and future status
Abstract: High-dose melphalan with autologous stem cell support has been an integral part of myeloma therapy for more than 25 years, either as salvage therapy or as consolidation of an initial remission. Although multiple phase 3 trials have demonstrated that this therapy results in higher response rates and longer remission times than conventional chemotherapy, the use of thalidomide, lenalidomide, and bortezomib as induction therapy has limited the clinical relevance of these trials. Moreover, ongoing trials have shown that initial induction therapy may affect transplantation outcome, and that long-term disease control can be achieved in a substantial number of patients with a variety of posttransplantation maintenance therapies. This article summarizes the results of ongoing and recently published clinical trials and describes how they have affected current transplantation recommendations.
Keywords: transplantation, homologous; review; methodology; multiple myeloma; stem cell transplantation; standard; transplantation, autologous; allotransplantation; induction chemotherapy; autotransplantation
Journal Title: Hematology-American Society of Hematology Education Program
Volume: 2011
Issue: 17 Suppl. 1
ISSN: 1520-4391
Publisher: American Society of Hematology  
Date Published: 2011-04-01
Start Page: 191
End Page: 196
Language: English
PUBMED: 22160033
PROVIDER: scopus
DOI: 10.1182/asheducation-2011.1.191
DOI/URL:
Notes: --- - "Export Date: 1 May 2012" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Sergio Andres Giralt
    535 Giralt